Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOGMES: Pegylated liposomal doxorubicin as first-line treatment in metastatic breast cancer in patients over 70 years
2007-002736-28Phase 2Completed
- Sponsor
- Arcagy-Gineco
- Start
- Sep 2007
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Arcagy-Gineco. Primary endpoints: Tumor response rate by RECIST and CA 15-3 and Treatment practicability. Started Sep 2007; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-002736-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002736-28.